Brentuximab Vedotin Consolidation Therapy after Autologous Stem-Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma: Multi-Center Retrospective Study [Meeting Abstract]

Ozbalak, MuratAkay, Olga MeltemPehlivan, MustafaYildiz, BirolUzay, AntYigenoglu, Tugce NurElverdi, Tugrul2023-01-122023-01-1220212152-26502152-2669https://hdl.handle.net/11454/79395[No Abstract Available]eninfo:eu-repo/semantics/closedAccessrelapsed and refractoryHodgkin lymphomabrentuximab vedotinautologous stem cell transplantationconsolidationBrentuximab Vedotin Consolidation Therapy after Autologous Stem-Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma: Multi-Center Retrospective Study [Meeting Abstract]Conference Object21S368S369WOS:000691910500283Q3